Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.
Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter R
GENERIC NAME |
TRADE NAME |
CONDITION |
STUDY CODE |
STUDY NAME |
ACCESS TO STUDY / PROTOCOL |
ACCESS TO RESULTS |
---|---|---|---|---|---|---|
RABBIT ANTI-THYMOCYTE GLOBULIN |
Thymoglobulin |
Myelodysplastic Syndrome |
ThymoHEM01206 |
RISE |
||
RAMIPRIL |
Triatec |
Heart diseases |
HOE498_3501 |
FOCUS |
||
RAMIPRIL |
Triatec |
Atherosclerosis |
HOE498_4099 |
HOPE |
||
RAMIPRIL |
Triatec |
Glomerulonephritis |
HOE498_6015 |
NA |
||
RAMIPRIL |
Triatec |
Hypertension |
HOE498_3E03 |
PHARAO |
||
RAMIPRIL |
Triatec |
Coronary Artery Disease |
RAMIP_L_03123 |
HOPETips |
||
RAMPIRIL + FELODIPINE |
Triapin |
Hypertension |
RAMFE_L_03420 |
NA |
||
RAMPIRIL + FELODIPINE |
Triapin |
Hypertension |
RAMIP_L_01961 |
RAFE HELP |
||
RASBURICASE |
Elitek, Fasturtec |
Hyperuricemia |
ACT5080 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Hyperuricemia |
ARD5290 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Tumor lysis syndrome |
EFC4978 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Cancer, Hyperuricemia |
EFC4978 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Hyperuricemia |
EFC4983 |
GRAAL2 |
||
RASBURICASE |
Elitek, Fasturtec |
Hyperuricemia |
EFC5339 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Tumor lysis syndrome |
L_8637 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Hematologic neoplasms |
L_8720 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Hyperuricemia |
L_9436 |
NA |
||
RASBURICASE |
Elitek, Fasturtec |
Hyperuricemia |
RASBU_L_00351 |
NA |
||
RHO-KINASE INHIBITOR |
Not marketed |
Erectile Dysfunction |
ACT10775 |
RHOKET |
||
RHO-KINASE INHIBITOR |
Not marketed |
Microvascular Coronary Artery Disease |
ACT14656 |
NA |
||
RHO-KINASE INHIBITOR |
Not marketed |
Chronic Kidney Disease |
TDR12446 |
NA |
||
RIFAPENTINE |
Priftin |
Tuberculosis |
INT12291 |
NA |
||
RILUZOLE |
Rilutek |
Amyotrophic Lateral Sclerosis |
RIL_CA1_401 |
CARE |
||
RILUZOLE |
Rilutek |
Amyotrophic Lateral Sclerosis |
RIL_DE1_201 |
NA |
||
RIFERMINOGENE PECAPLASMID |
Not marketed |
Critical limb ischemia |
EFC6145 |
TAMARIS |
||
RIMONABANT |
Acomplia |
Obesity |
ACT3801 |
NA |
||
RIMONABANT |
Acomplia |
Obesity |
DRI5747 |
NA |
||
RIMONABANT |
Acomplia |
Obesity |
EFC4733 |
RIO-EUROPE |
||
RIMONABANT |
Acomplia |
Obesity |
EFC4735 |
RIO-LIPIDS |
||
RIMONABANT |
Acomplia |
Obesity |
EFC4736 |
RIO-DIABETES |
||
RIMONABANT |
Acomplia |
Obesity |
EFC4743 |
RIO-NORTH AMERICA |
||
RIMONABANT |
Acomplia |
Smoking Cessation |
EFC4796 |
STRATUS-WW |
||
RIMONABANT |
Acomplia |
Obesity |
EFC4798 |
CIRRUS |
||
RIMONABANT |
Acomplia |
Diabetes, Type 2 |
EFC5593 |
ARPEGGIO |
||
RIMONABANT |
Acomplia |
Obesity Dyslipidemia |
EFC5823 |
ADAGIO |
||
RIMONABANT |
Acomplia |
Obesity |
EFC5827 |
STRADIVARIUS |
||
RIMONABANT |
Acomplia |
Obesity |
EFC6001 |
RIO-ASIA |
||
RIMONABANT |
Acomplia |
Obesity |
RIMON_R_00961 |
PRADO |
||
RISEDRONATE SODIUM |
Actonel |
Osteoporosis, Postmenopausal |
EFC6063 (HMR4003B/4003) |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Osteoporosis, Postmenopausal |
EFC6064 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Osteoporosis |
HMR4003B_3507 |
OSMAUSE |
||
RISEDRONATE SODIUM |
Actonel |
Osteoporosis |
HMR4003B_4001 |
IMPACT |
||
RISEDRONATE SODIUM |
Actonel |
Osteoporosis, Postmenopausal |
HMR4003F/4001 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Osteoporosis, Postmenopausal |
RISED_L_01930 |
SOLID |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_2501 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_4027 |
ACTIVATE |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_4031 |
POWER |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_4033 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_4034 |
OPTAMISE |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_4035 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
HMR4003B_4036 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
RISED_L_01054 |
NA |
||
RISEDRONATE SODIUM |
Actonel |
Bone Diseases |
RISED_L_01686 |
ROSPA |
||
ROMILKIMAB |
Not marketed |
Idiopathic Pulmonary Fibrosis |
DRI11772 |
ESTAIR |
||
ROMILKIMAB |
Not marketed |
Systemic Sclerosis |
ACT14604 |
|
||
ROMILKIMAB |
Not marketed |
Idiopathic Pulmonary Fibrosis |
TDR11326 |
NA |
||
References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted